Antares Pharma up 6% premarket on Q3 beat

Antares Pharma (NASDAQ:ATRS) Q3 results:

Revenue: $24.7M (+113%) driven by Xyosted (sales of $7.0M) demand.

Net income: $1.0M (+182%); EPS: $0.01 (+200%).

2019 guidance: Revenue: $115M – 120M from $100M – 110M.

Previously: Antares Pharma EPS beats by $0.03, beats on revenue (Nov. 5)

https://seekingalpha.com/news/3514441-antares-pharma-6-percent-premarket-q3-beat